In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...
Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...
Investigators at Memorial Sloan Kettering Cancer Center (MSK) have published results from a clinical trial that found people with recurrent multiple myeloma may benefit from receiving chimeric antigen ...
VIENNA, Va., May 22, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback